Monitoring residual myeloma: High-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?

American Journal of Clinical Pathology

Volumn 134, Issue 1, 2010, Pages 139-145

  Tatsas, Amanda D ^a   Jagasia, Madan H ^a   Chen, Heidi ^b   McCurley, Thomas L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow biopsy; Electrophoresis; Myeloma; Residual disease

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYELOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; URINE;

ADULT; AGED; BIOPSY; BONE MARROW CELLS; ELECTROPHORESIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM, RESIDUAL; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77954482854     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP69TCAVDGSCWI     Document Type: Article

References (25)

1. Zhao X, Huang Q, Slovak M, et al. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol. 2006;125:895-904.
2. Billadeau D, Van NB, Kimlinger T, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood. 1996;88:289-296.
3. Sukpanichnant S, Cousar JB, Leelasiri A, et al. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol. 1994;25:308-318.
4. Keren DR. High Resolution Electrophoresis and Immunofixation: Techniques and Interpretation. Boston, MA: Elsevier; 1987.
5. Blade J, Samson D, Reece D, et al; for the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant), Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR (International Bone, Marrow Transplant Registry), and ABMTR (Autologous Blood, and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
7. Rasmussen T, Knudsen LM, Huynh TK, et al. Molecular and clinical follow-up after treatment of multiple myeloma. Acta Haematol. 2004;112:105-110.
8. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112:4235-4246.
9. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-438.
10. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
11. Owen RG, Johnson RJ, Rawstron AC, et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol. 1996;49:672-675.
12. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94:217-227.
13. Keren DF, Warren JS, Lowe JB. Strategy to diagnose monoclonal gammopathies in serum: high-resolution electrophoresis, immunofixation, and kappa/lambda quantification. Clin Chem. 1988;34:2196-2201.
14. Keren DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch Pathol Lab Med. 1999;123:126-132.
15. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111:4908-4915.
16. Mosbauer U, Ayuk F, Schieder H, et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation [letter]. Haematologica. 2007;92:275-276.
17. Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res. 2005;11:8706-8714. (Pubitemid 43005920)
18. Jaskowski TD, Litwin CM, Hill HR. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin Vaccine Immunol. 2006;13:277-280.
19. Chee CE, Kumar S, Larson DR, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009;114:2617-2618.
20. Al-Quran SZ, Yang L, Magill JM, et al. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Hum Pathol. 2007;38:1779-1787.
21. Catrou PG. Is that lab necessary? Am J Clin Pathol. 2006;126:335-336.
22. May TA, Clancy M, Critchfield J, et al. Reducing unnecessary inpatient laboratory testing in a teaching hospital. Am J Clin Pathol. 2006;126:200-206.
23. National Health Expenditure Data. Centers for Medicare & Medicaid Services Web page. http://www.cms.hhs.gov/NationalHealthExpendData/02- NationalHealthAccountsHistorical.asp. 2009.
24. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-224.
25. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.